US Rifaximin Prices Decline 1.06% in July 2026 as Lower Origin Costs Offset Freight Inflation

The US Rifaximin market softened modestly in July 2026, reversing the slight increase recorded in June as higher Chinese inventories encouraged exporters to reduce offers. Lower Chinese quotations improved the cost position of US importers and outweighed the impact of higher trans-Pacific freight expenses. Demand remained broadly supportive, driven by routine outpatient prescription activity and steady pharmaceutical procurement, although hospital purchasing stayed restrained and buyers generally avoided building substantial inventories. Supply remained adequate, with competitively priced Chinese material continuing to dominate import discussions. Looking ahead to August, the Rifaximin market is expected to remain under downward pressure as inventory normalization and competitive Asian export offers continue to weigh on pricing. However, higher logistics costs, potential maintenance at Asian facilities, and eventual restocking by US buyers could provide support and contribute to a gradual recovery later in the year. The August outlook remains subject to freight movements, inventory cycles, production conditions, and geopolitical disruptions affecting trans-Pacific trade.